INTRODUCTION {#SEC1}
============

Single nucleotide polymorphisms (SNPs) are the most frequent genetic variants in humans and represent a valuable resource for investigating the genetic basis of diseases ([@B1]). Genome-wide association studies (GWAS) have found abundant SNPs associated with various traits and diseases, but most of risk loci lack clear molecular mechanisms ([@B2],[@B3]). Expression quantitative trait locus (eQTL) studies have been employed to identify SNPs that may influence the expression levels of genes, thereby contributing to the phenotype outcome ([@B4]). However, only a moderate proportion of GWAS-identified loci are strong eQTLs ([@B7]), which might be partly due to the small sample sizes, the tissues studied, and a focus on overall gene level expression measurements without consideration of transcript isoforms ([@B8]).

Alternative splicing (AS) is a molecular mechanism that produces multiple distinct transcript isoforms from a single gene. The invention of RNA sequencing greatly facilitated the identification of AS on a genomic scale ([@B9]). In human, AS can occur in ∼90% of genes in a cell type-, condition- or species-specific manner, which is thought to extensively increase the number of proteins over the number of genes in a genome ([@B10],[@B11]). In cancer, aberrant splicing patterns are frequently observed and known to contribute to carcinogenesis, de-differentiation and metastasis ([@B12]). Many cancer-specific transcript isoforms have been identified ([@B13]). For example, an alternatively spliced transcript isoform of the gene encoding spleen tyrosine kinase is frequently expressed in breast cancer cells but never in matched normal tissues ([@B14]). Available evidence reveals that at least 20% of disease-causing single base-pair mutations affect splicing ([@B15]). Common genetic variation that affects splicing regulation, referred to as splicing quantitative trait loci (sQTLs), can lead to differences in alternative splicing between individuals, consequently influence disease susceptibility and drug response ([@B16]). Thus, the identification of sQTLs, especially in cancer tissues, might represent an important step toward fully understanding the contribution of genetic variants in tumorigenesis and development.

Because of the significance of sQTLs, several studies have performed genome-wide sQTL identifications on different human tissues, such as whole blood and brain ([@B8],[@B17]). These large-scale transcriptome studies using high-throughput genotyping method and deep RNA sequencing have revealed widespread sQTLs throughout the genome. However, no database comprehensively provides sQTLs for a large number of cancer samples. To bridge this gap, we have developed a computational pipeline to systematically identify sQTLs in 33 cancer types incorporating 9026 tumor samples from The Cancer Genome Atlas (TCGA). We identified millions of sQTLs across cancer types, and constructed a user-friendly database, CancerSplicingQTL (<http://www.cancersplicingqtl-hust.com/>) for users to conveniently browse, search and download data of interest.

DATA COLLECTION AND PROCESSING {#SEC2}
==============================

Values of splicing events collection and processing {#SEC2-1}
---------------------------------------------------

Percent Spliced In (PSI) values of each AS event were downloaded from the TCGASpliceSeq (<http://projects.insilico.us.com/TCGASpliceSeq/PSIdownload.jsp>) with default parameter ([@B20]). PSI value is a common, intuitive ratio for quantifying splicing events ([@B11]). The value is calculated by the transcript element present divided by the total number of reads covering the splicing event (Figure [1A](#F1){ref-type="fig"}). Six types of AS events were analyzed in CancerSplicingQTL, including skipped exon, retained intron, alternative donor sites, alternative acceptor sites, alternate terminator and alternate promoter (Figure [1B](#F1){ref-type="fig"}). For each cancer type, probes were filtered using the following criteria: (i) the rate of missing PSI value \>0.1, (ii) mapping to locations on sex chromosome (Figure [1E](#F1){ref-type="fig"}). Finally, an average of 34 942 AS events per cancer type were used for analyses. To minimize the effects of outliers on the regression scores ([@B21]), the values for each probe across samples per cancer type were transformed into a standard normal distribution based on rank.

![Identification of sQTLs in the CancerSplicingQTL database. (**A**) The definition of Percent Spliced In values ([@B20]). PSI is the ratio of reads indicating the presence of a transcript element versus the total reads covering the event. In this example, the PSI value is 0.6, indicating that the exon 2 is included in approximately 60% of the transcripts in the sample. (**B**) The types of splice events analyzed in SplicingQTL. (**C**) Genotype data collection and processing. (**D**) Covariates included in sQTL mapping. (**E**) The values of splice events collection and processing. (**F**) sQTLs, survival-associated sQTLs and GWAS-related sQTLs identification.](gky954fig1){#F1}

Genotype data collection, imputation and processing {#SEC2-2}
---------------------------------------------------

We downloaded genotype data (level 2) of 10 944 tumor samples from the TCGA data portal (<https://portal.gdc.cancer.gov/>), which detected the genotypes using Affymetrix SNP Array 6.0 containing 898 620 SNPs for each sample. Of these samples, 9026 samples were available with PSI data. To increase the power for sQTL discovery, we imputed autosomal variants for all samples in each cancer type using IMPUTE2, with 1000 Genomes Phase 3 as the reference panel as described in our previous study ([@B24]). To improve computation efficiency, we used the two-step procedure of IMPUTE2, which includes pre-phasing and the imputation of the phased data. Following criteria were used to exclude SNPs: (i) imputation confidence score, INFO \< 0.4, (ii) minor allele frequency (MAF) \< 5%, (iii) SNP missing rate ≥ 5% for best-guessed genotypes at posterior probability ≥ 0.9 and (iv) Hardy--Weinberg Equilibrium *P*-value \< 1 × 10^−6^ estimated by Hardy--Weinberg R package (Figure [1C](#F1){ref-type="fig"}). After imputation and quality filtering, an average of 4 516 897 genotypes per cancer type were remained in the sQTL analyses.

Covariates {#SEC2-3}
----------

In QTL analyses, covariates are often included to correct for the known and unknown confounders and increase the sensitivity of analyses ([@B25]). The top five principal components (PC) calculated by smartPCA in the EIGENSOFT program ([@B26]) were included to control for ethnicity differences, as they account for 10% of the variation explained with diminishing returns (0.5% or smaller contribution) for subsequent PCs, which are sufficient to represent the major population structure found in the TCGA dataset. Furthermore, to remove the hidden batch effects and other confounders from the AS data, we used PEER software ([@B27]) to infer hidden determinants, and selected the first 15 PEER factors from the AS data as covariates. The hidden batch effects and ethnic differences respectively accounted for an average of 19.9% and 1.19% of contribution to PSI variance in all cancers, which were described in details at the [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. Other common confounders, specifically age, sex, and tumor stage, were included as additional covariates ([@B22],[@B28],[@B29]) (Figure [1D](#F1){ref-type="fig"}).

Identification of sQTLs {#SEC2-4}
-----------------------

For each cancer type, the effects of genetic variation on AS events were evaluated by linear regression using MatrixEQTL ([@B30]) (Figure [1F](#F1){ref-type="fig"}). Pairwise associations between each SNP and its splicing events around ±100 kb were calculated. The location (hg19) of splicing events was downloaded from TCGASpliceSeq database (<http://projects.insilico.us.com/TCGASpliceSeq/TCGA_SpliceSeq_Gene_Structure.zip>), and the SNP location (hg19) was obtained from dbSNP (<https://www.ncbi.nlm.nih.gov/projects/SNP/>). SNPs with false discovery rates (FDR) \< 0.05 calculated by MatrixEQTL were defined as sQTLs ([@B17]).

Identification of survival-associated sQTLs {#SEC2-5}
-------------------------------------------

As many AS are involved in cancer prognosis ([@B31]), sQTLs may alter gene splicing and thereby influence the prognosis. To prioritize promising sQTLs, we additionally identified sQTLs that might be associated with patient survival times. For each sQTL, we examined the associations between the sQTL and patient overall survival times. For each sQTL, samples were classified into three groups: homozygous genotype AA, heterozygous genotype Aa and homozygous genotype aa (A and a represent two alleles of one SNP). The log-rank test was used to examine the differences in survival time, and Kaplan--Meier (KM) curves were plotted to represent the survival times for each group. sQTLs with FDR \< 0.05 were defined as survival-associated sQTLs.

Identification of GWAS-associated sQTLs {#SEC2-6}
---------------------------------------

The identification of causal variants is a major challenge for post GWAS studies ([@B32]). Thus we integrated the sQTLs with known GWAS risk loci to facilitate interpretation of the function of genomic variants. We downloaded all the known risk tag SNPs identified in GWAS studies from the National Human Genome Research Institute (NHGRI) GWAS catalog (<http://www.ebi.ac.uk/gwas/>, accessed by 1 March 2018) ([@B2]). Then we obtained GWAS linkage disequilibrium (LD) regions of these risk tag SNPs from SNAP (<https://personal.broadinstitute.org/plin/snap/ldsearch.php>) ([@B33]) with parameters (SNP data set: 1000 Genomes; *r*^2^ (the square of the Pearson correlation coefficient of linkage disequilibrium) threshold: 0.5; population panel: CEU (Utah Residents with Northern and Western European Ancestry), and distance limit: 100 kb). sQTLs that overlapped with GWAS tag SNPs and LD SNPs were defined as GWAS-related sQTLs.

DATABASE CONTENT {#SEC3}
================

Samples in CancerSplicingQTL {#SEC3-1}
----------------------------

In total, CancerSplicingQTL included 9026 tumor samples with both genotype data and PSI data available for 33 cancer types (Figure [2A](#F2){ref-type="fig"}). The sample size for each cancer type ranged from 36 for cholangiocarcinoma (CHOL) to 1090 for invasive breast carcinoma (BRCA) (Table [1](#tbl1){ref-type="table"}). After imputation and quality control of the genotype data, an average of 4 516 897 SNPs per each cancer type were used for analyses, ranging from 2746 175 for BRCA to 5 120 270 for acute myeloid leukemia (LAML). After removing AS events with a rate of missing PSI beta value \> 0.1 or mapping to sex chromosome, an average of 34 942 splicing events per cancer type were used for analyses, ranging from 24 707 for uterine corpus endometrial carcinoma (UCEC) to 43 937 for esophageal carcinoma (ESCA).

![sQTL statistics. (**A**) The cancer types included in the study. (**B**) The positive correlation between the number of sQTLs and the sample size. (**C**) The distribution of sQTLs. Each cyan dot indicates a sQTL plotted according to its distance from the corresponding AS event and statistical significance of its association with AS (--log~10~*P*-value). Red line indicates density of sQTLs according to their distance from the corresponding AS event. (**D**) Bar plot indicates proportions of sQTLs affecting different AS type (AA: alternative acceptor sites, AD: alternative donor sites, AP: alternate promoter, AT: alternate terminator, ES: skipped exon and RI: retained intron).](gky954fig2){#F2}

###### 

Overview of sQTLs in each cancer type included in SplicingQTL

  Cancer type   Disease full name                                                  No. of Sample   No. of genotype   No. of splicing   sQTLs    Affected splicing   sQTL pairs   Survival\_ sQTLs   GWAS\_ sQTLs
  ------------- ------------------------------------------------------------------ --------------- ----------------- ----------------- -------- ------------------- ------------ ------------------ --------------
  ACC           Adrenocortical carcinoma                                           77              3567953           26620             17752    913                 24950        7                  4930
  BLCA          Bladder urothelial carcinoma                                       406             4183896           32125             168597   6180                289420       157                44333
  BRCA          Breast invasive carcinoma                                          1090            2746175           38428             253767   11961               506672       64                 64008
  CESC          Cervical squamous cell carcinoma and endocervical adenocarcinoma   250             4272427           33443             118989   4847                190429       412                31143
  CHOL          Cholangiocarcinoma                                                 36              4012151           31208             64       9                   64           0                  5
  COAD          Colon adenocarcinoma                                               285             4491421           27466             152518   6048                255470       294                39233
  DLBC          Lymphoid neoplasm diffuse large B-cell lymphoma                    48              4845460           26277             4445     206                 5641         0                  1254
  ESCA          Esophageal carcinoma                                               180             4463210           43937             138960   5324                214082       764                36443
  GBM           Glioblastoma multiforme                                            150             4556997           38904             126023   4724                197274       817                33604
  HNSC          Head and neck squamous cell carcinoma                              499             4247759           35648             236904   8109                418356       698                60692
  KICH          Kidney chromophobe                                                 66              3771773           39171             25251    1329                34571        388                6542
  KIRC          Kidney renal clear cell carcinoma                                  527             4579516           39696             325766   10887               600508       493                80279
  KIRP          Kidney renal papillary cell carcinoma                              290             4894174           33438             162228   6001                264080       1115               41681
  LAML          Acute myeloid leukemia                                             122             5120270           29804             35478    1348                51024        152                11042
  LGG           Lower grade glioma                                                 514             4632416           41896             354837   11254               675128       1062               85201
  LIHC          Liver hepatocellular carcinoma                                     369             4156507           26210             119209   4407                194309       229                30134
  LUAD          Lung adenocarcinoma                                                512             4383840           37236             255517   8777                455348       147                67226
  LUSC          Lung squamous cell carcinoma                                       500             3742393           39640             242335   9123                437645       65                 62268
  MESO          Mesothelioma                                                       87              4784881           36010             49305    1734                68126        809                13856
  OV            Ovarian serous cystadenocarcinoma                                  293             2975439           41415             149571   6769                254127       133                39361
  PAAD          Pancreatic adenocarcinoma                                          176             4985375           39104             140937   4946                224001       771                37996
  PCPG          Pheochromocytoma and Paraganglioma                                 168             4707250           34321             112116   4400                180122       1156               29132
  PRAD          Prostate adenocarcinoma                                            485             4823458           37654             313993   10268               581617       1643               75506
  READ          Rectum adenocarcinoma                                              93              4516897           29274             52896    2064                76387        204                14965
  SARC          Sarcoma                                                            248             4081096           33922             124542   4944                202118       737                33246
  SKCM          Skin cutaneous melanoma                                            101             4865378           34942             53912    2014                74913        280                15180
  STAD          Stomach adenocarcinoma                                             408             4306085           41433             207947   7311                338590       280                53307
  TGCT          Testicular germ cell tumors                                        144             4791125           35758             107451   3815                166457       305                28328
  THCA          Thyroid carcinoma                                                  493             4870332           39754             359916   11265               683697       1842               86793
  THYM          Thymoma                                                            107             4892278           33234             85317    3203                132081       935                23473
  UCEC          Uterine corpus endometrial carcinoma                               166             4941208           24707             61884    2773                92641        372                16929
  UCS           Uterine carcinosarcoma                                             56              3888384           32022             6586     393                 8485         25                 1729
  UVM           Uveal melanoma                                                     80              4737551           32067             34585    1348                47524        716                10313

sQTLs in CancerSplicingQTL {#SEC3-2}
--------------------------

The CancerSplicingQTL mainly contains three datasets that are sQTLs, survival-sQTLs and GWAS-sQTLs. In the sQTL analysis, the associations between each SNP and AS events within the ±100 kb window around the SNP were analyzed for sQTL mapping by linear regression. We totally identified 7 945 857 sQTL-AS pairs at a per-tissue FDR \< 0.05 in 33 cancer types. In total, there are 4 599 598 sQTLs across cancer types, ranging from 64 in CHOL to 574 577 in thyroid carcinoma (THCA), with a median of 124 542 sQTLs per cancer type (Table [1](#tbl1){ref-type="table"}). The number of sQTLs was significantly correlated with the number of samples (Spearman correlation *Rs* = 0.96, *P*-value = 1.44 × 10^−18^, Figure [2B](#F2){ref-type="fig"}). These sQTLs affect a median of 4847 AS events of 2857 unique genes per cancer type. Most of sQTLs were centered on AS events and 50% of sQTLs located at ±31 kb region flanking the AS events (Figure [2C](#F2){ref-type="fig"}). 42.8% of sQTLs were associated with multiple AS events, and of these affected AS events, 33.6%, 27.3% and 18.7% were alternate terminator (AT), exon skip (ES) and alternate promoter (AP), respectively (Figure [2D](#F2){ref-type="fig"}).

The germline variants derived from genotype imputation accounted for an average of 88.5% of sQTLs in all cancer types, ranging from 84.1% in BRCA to 90.1% in LAML ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Additionally, we calculated the replication ratio of sQTL-splicing pairs in one cancer across other cancer types, finding an average of 45.9% of sQTL-splicing pairs replicate across other cancer types ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). To compare the difference between before and after the correction of the batch effects, we respectively calculated the sQTLs between before and after the correction. We found that there were an average of 23.5% of sQTLs loss and 26.6% of sQTLs gain in all cancers, between before and after the correction of the batch effects ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

To prioritize promising sQTLs, we linked sQTLs to patient survival times and known GWAS loci. We found 17 072 sQTLs associated with patient overall survival times across different cancer types at FDR \< 0.05. The number of survival-sQTLs ranged from 0 in CHOL and lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) to 1643 in prostate adenocarcinoma (PRAD). We also linked sQTL results to NHGRI GWAS Catalog data and found 1 180 132 sQTLs that overlapped with GWAS linkage disequilibrium (LD) regions of one or multiple traits.

DATABASE ORGANIZATION AND WEB INTERFACE {#SEC4}
=======================================

CancerSplicingQTL was built based on the NodeJS 8.10.0 (<https://nodejs.org/en/>) framework with MongoDB 3.6.5 (<https://www.mongodb.com/>) as its database engine. It runs on a Linux-based Nginx Web server, while ReactJS (<https://reactjs.org/>), a modern JavaScript library, is used for building user interfaces. We have tested it on Google Chrome (preferred), Firefox or Apple Safari browsers. The SplicingQTL website is available online (<http://www.cancersplicingqtl-hust.com/>) and requires no registration.

We provided a user-friendly web interface that facilitates searching, browsing and downloading the three datasets. Users can enter the 'sQTL/survival-sQTL/GWAS-sQTL' pages by clicking on the corresponding button in the browser bar (Figure [3A](#F3){ref-type="fig"}) or on hyperlinks embedded in the corresponding images in the 'Modules' section on the 'home' page (Figure [3C](#F3){ref-type="fig"}). Two query sections 'Single Search' and 'Batch Search' are provided for comprehensive queries across all three datasets (Figure [3B](#F3){ref-type="fig"}). In the 'Single Search' section, users can select a specific cancer type (e.g. BRCA) and input an SNP ID (e.g. rs936227), gene symbol (e.g. ULK3) or genomic region (e.g. chr15:75 100 000--75 200 000) to search sQTLs across all datasets. If users do not select cancer type, it will return results for all cancer types. The 'Batch Search' section allows users to input multiple cancer types, SNPs, genes or genomic regions of interest. For instance, inputting 'rs936227' and 'rs9989230' in the 'SNP ID' box, will return a complete list of matched entries across cancer types. In addition, a summary of the sample size, sQTL number and AS type distribution is also shown on the 'home' page. Putting the cursor over a cancer name on the-hand side human anatomy diagram, the matched results will show on the right-hand side figures. All data in the database can be downloaded from the 'Download' page. A detailed tutorial showing how the data were collected and processed is available on the 'Help' page. CancerSplicingQTL welcomes any feedback by email via the 'Contact' page.

![Overview of the CancerSplicingQTL database. (**A**) Browser bar in SplicingQTL. (**B**) The single and batch search boxes in SplicingQTL. (**C**) Three modules in SplicingQTL, including sQTLs, survival-associated sQTLs, and GWAS-related sQTLs. (**D**) An example of sQTL results on the 'sQTL' page. (**E**) An example of survival-sQTL results in 'survival-sQTL' page. (**F**) An example of a sQTL boxplot on the 'sQTL' page. (**G**) An example of a Kaplan--Meier plot on the 'survival-sQTL' page.](gky954fig3){#F3}

Query on the 'sQTLs' page {#SEC4-1}
-------------------------

To query sQTLs, CancerSplicingQTL allows users to search by selecting a cancer type from a pull-down menu, or by entering a SNP ID or gene symbol. After users click the 'Search' button, the query results are displayed in a table showing SNP ID, SNP genomic position, SNP alleles, related gene symbol, splicing type, splicing exon, splicing ID (the same as TCGASpliceSeq annotation), splice position, beta value (effect size of SNP on PSI value), *r* value (correlation coefficient) and *P*-value of sQTL (Figure [3D](#F3){ref-type="fig"}). By clicking the hyperlink 'Box Plot' on the right of each record, a vector diagram of a boxplot will display the association between SNP genotypes and normalized PSI values. For example, our analysis showed that at *XPNPEP3* first exon, the PSI values of individuals carrying the homozygote rs5758123 aa is significantly higher than that of individuals carrying the homozygote rs5758123 AA and heterozygous rs5758123 Aa in stomach adenocarcinoma (*P*-value = 1.34 × 10^−53^, Figure [3G](#F3){ref-type="fig"}).

Query on the 'survival-sQTLs' page {#SEC4-2}
----------------------------------

A table with SNP ID, SNP genomic position, SNP alleles, Log-rank test *P*-value, and median survival time for each genotype group is displayed on the survival-sQTLs page (Figure [3E](#F3){ref-type="fig"}). Search boxes are designed to retrieve specific cancer types and SNPs. If users select a specific cancer type or input a gene or SNP ID, the table will be reconstructed to display the results of the query. Each record embeds a hyperlink 'KM Plot', showing the association between SNP genotypes and overall survival times. For example, our analysis showed that patients with rs7597845 AA allele have a better prognosis than other patients with breast cancer (*P*-value = 9.09 × 10^−6^, Figure [3F](#F3){ref-type="fig"}).

Query on the 'GWAS-sQTLs' page {#SEC4-3}
------------------------------

A complete list of the SNP information, regulated splice site, related gene information and related GWAS-traits are provided on the 'GWAS-sQTL' page. Search boxes are designed to retrieve a specific cancer type, phenotype or SNP. In addition, users can select a different LD threshold from the 'LD' dropdown box to prioritize SNPs. For example, the GWAS-catalog has collected 263 tag SNPs of breast cancer risk loci. We found that 83 tag SNPs have 1402 sQTLs in their LD regions (*r*^2^ ≥ 0.5) affecting the splicing events of 100 genes. Causal variants of breast cancer could be existed among these sQTLs.

SUMMARY AND FUTURE DIRECTIONS {#SEC5}
=============================

In summary, CancerSplicingQTL is a comprehensive sQTL resource that uses large cancer samples to evaluate the effects of genetic variants on gene splicing. It provides a user-friendly interface for users to query, browse, and download sQTLs. To the best of our knowledge, CancerSplicingQTL is the first public database focusing on cancer-specific sQTLs. Millions of vector diagrams of sQTL box plots and KM plots are provided for scientific usage. We also identified numerous sQTLs associated with patient survival times or located in known GWAS loci that will be promising candidates for genetic research. Biologists can download entire datasets for further integrative studies.

Cancer genomics studies are developing rapidly ([@B34],[@B35]), and we expect the number of cancer samples with genotype and splicing profiles to increase dramatically. In the future, we will continue to update CancerSplicingQTL to include more cancer samples and maintain it as a useful resource for the research community. We will add more genetic and splicing information into the database. We believe that CancerSplicingQTL will be an important resource for human cancer genetics, providing opportunities to bridge the knowledge gap from variants in sequence to phenotypes.

Supplementary Material
======================

###### 

Click here for additional data file.
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